Evidence map›Paper›PMID 19920826›Full record

ArticleBritish journal of cancer2010

Relation of risk of contralateral breast cancer to the interval since the first primary tumour.

C Rubino, R Arriagada, S Delaloge, M G Lê

Abstract read
In one paragraph

Article in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Breast cancer risks and risk prediction models.Breast care (Basel, Switzerland) · 2015
    Review
  10. Recent BRCAPRO upgrades significantly improve calibration.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014
    Article
  11. Article
  12. Article
  13. Article
  14. Breast cancer in young women.Nature reviews. Clinical oncology · 2012
    Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

C RubinoInstitut National de la Santé et de la Recherche Médicale (INSERM), Unit 605, Villejuif Cedex 94805, France. carole.rubino@igr.fr
R Arriagada
S Delaloge
M G Lê

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is no consensus on how to separate contralateral breast cancer (CBC) occurring as distant spread of the primary breast cancer (BC) from an independent CBC.

methodsWe used standardised incidence ratios (SIRs) to analyse the variations in the risk of CBC over time among 6629 women with BC diagnosed between 1954 and 1983. To explore the most appropriate cutoff to separate the two types of CBC, we analysed the deviance between models including different cutoff points as compared with the basal model with no cutoff date. We also performed a prognostic study through a Cox model.

resultsThe SIR was much higher during the first 2 years of follow-up than afterwards. The best cutoff appeared to be 2 years. The risk of early CBC was linked to tumour spread and the risk of late CBC was linked to age and to the size of the tumour. Radiotherapy was not selected by the model either for early or late CBC risk.

conclusionA clearer pattern of CBC risk might appear if studies used a similar cutoff time after the initial BC.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCombined Modality TherapyDiagnosis, DifferentialFemaleFollow-Up StudiesHumansIncidenceLymphatic IrradiationMastectomyMiddle AgedNeoplasms, Multiple PrimaryNeoplasms, Radiation-Induced

Identifiers

PMID19920826
PMCPMC2813760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.